Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 150

1.

Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.

Feng X, Dong K, Pham D, Pence S, Inciardi J, Bhutada NS.

J Clin Pharm Ther. 2013 Aug;38(4):301-8. doi: 10.1111/jcpt.12061. Epub 2013 Apr 3.

PMID:
23550846
[PubMed - indexed for MEDLINE]
2.

Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.

Knoebel RW, Lo M, Crank CW.

J Oncol Pharm Pract. 2011 Sep;17(3):147-54. doi: 10.1177/1078155210364180. Epub 2010 Mar 23.

PMID:
20332174
[PubMed - indexed for MEDLINE]
3.

Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.

McBride A, Lathon SC, Boehmer L, Augustin KM, Butler SK, Westervelt P.

Pharmacotherapy. 2013 Mar;33(3):295-303. doi: 10.1002/phar.1198.

PMID:
23456733
[PubMed - indexed for MEDLINE]
4.

Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.

McDonnell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD.

Pharmacotherapy. 2006 Jun;26(6):806-12.

PMID:
16716134
[PubMed - indexed for MEDLINE]
5.

Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.

Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, Van den Berg H.

Cancer. 2003 Sep 1;98(5):1048-54.

PMID:
12942574
[PubMed - indexed for MEDLINE]
Free Article
6.

Single-dose rasburicase for tumour lysis syndrome in adults: weight-based approach.

Campara M, Shord SS, Haaf CM.

J Clin Pharm Ther. 2009 Apr;34(2):207-13. doi: 10.1111/j.1365-2710.2008.00994.x.

PMID:
19250141
[PubMed - indexed for MEDLINE]
7.

Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.

Annemans L, Moeremans K, Lamotte M, Garcia Conde J, van den Berg H, Myint H, Pieters R, Uyttebroeck A.

Support Care Cancer. 2003 Apr;11(4):249-57. Epub 2003 Feb 4.

PMID:
12673464
[PubMed - indexed for MEDLINE]
8.

Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.

Cheuk DK, Chiang AK, Chan GC, Ha SY.

Cochrane Database Syst Rev. 2014 Aug 14;8:CD006945. doi: 10.1002/14651858.CD006945.pub3. Review.

PMID:
25121561
[PubMed - indexed for MEDLINE]
9.

Economic implications of rasburicase treatment in adult patients with tumour lysis syndrome.

Eaddy M, Seal B, Tangirala K, Davies EH, O'Day K.

Appl Health Econ Health Policy. 2012 Nov 1;10(6):431-40. doi: 10.2165/11634230-000000000-00000.

PMID:
23013428
[PubMed - indexed for MEDLINE]
10.

Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.

Cortes J, Moore JO, Maziarz RT, Wetzler M, Craig M, Matous J, Luger S, Dey BR, Schiller GJ, Pham D, Abboud CN, Krishnamurthy M, Brown A Jr, Laadem A, Seiter K.

J Clin Oncol. 2010 Sep 20;28(27):4207-13. doi: 10.1200/JCO.2009.26.8896. Epub 2010 Aug 16.

PMID:
20713865
[PubMed - indexed for MEDLINE]
Free Article
11.

Role of i.v. allopurinol and rasburicase in tumor lysis syndrome.

Holdsworth MT, Nguyen P.

Am J Health Syst Pharm. 2003 Nov 1;60(21):2213-22; quiz 2223-4. Review.

PMID:
14619112
[PubMed - indexed for MEDLINE]
12.

A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.

Vadhan-Raj S, Fayad LE, Fanale MA, Pro B, Rodriguez A, Hagemeister FB, Bueso-Ramos CE, Zhou X, McLaughlin PW, Fowler N, Shah J, Orlowski RZ, Samaniego F, Wang M, Cortes JE, Younes A, Kwak LW, Sarlis NJ, Romaguera JE.

Ann Oncol. 2012 Jun;23(6):1640-5. doi: 10.1093/annonc/mdr490. Epub 2011 Oct 19.

PMID:
22015451
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.

Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS.

Blood. 2001 May 15;97(10):2998-3003.

PMID:
11342423
[PubMed - indexed for MEDLINE]
Free Article
14.

Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.

Lopez-Olivo MA, Pratt G, Palla SL, Salahudeen A.

Am J Kidney Dis. 2013 Sep;62(3):481-92. doi: 10.1053/j.ajkd.2013.02.378. Epub 2013 May 14. Review.

PMID:
23684124
[PubMed - indexed for MEDLINE]
15.

[Rasburicase versus allopurinol in the treatment of hyperuricaemia in tumour lysis syndrome].

Tatay VS, Castilla JD, Ponce JM, Hurtado JM, Cantero E, Abril ML.

An Pediatr (Barc). 2010 Feb;72(2):103-10. doi: 10.1016/j.anpedi.2009.10.011. Epub 2009 Dec 21. Spanish.

PMID:
20022572
[PubMed - indexed for MEDLINE]
Free Article
16.

Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.

Vines AN, Shanholtz CB, Thompson JL.

Ann Pharmacother. 2010 Oct;44(10):1529-37. doi: 10.1345/aph.1P296. Epub 2010 Sep 14.

PMID:
20841516
[PubMed - indexed for MEDLINE]
17.

Use of single-dose rasburicase in an obese female.

Arnold TM, Reuter JP, Delman BS, Shanholtz CB.

Ann Pharmacother. 2004 Sep;38(9):1428-31. Epub 2004 Aug 3.

PMID:
15292497
[PubMed - indexed for MEDLINE]
18.

Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase.

Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D.

Eur J Haematol. 2008 Apr;80(4):331-6. Epub 2007 Dec 10.

PMID:
18081720
[PubMed - indexed for MEDLINE]
19.

Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.

Coiffier B, Mounier N, Bologna S, Fermé C, Tilly H, Sonet A, Christian B, Casasnovas O, Jourdan E, Belhadj K, Herbrecht R; Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma.

J Clin Oncol. 2003 Dec 1;21(23):4402-6. Epub 2003 Oct 27.

PMID:
14581437
[PubMed - indexed for MEDLINE]
20.

Rasburicase: a new approach for preventing and/or treating tumor lysis syndrome.

Bessmertny O, Robitaille LM, Cairo MS.

Curr Pharm Des. 2005;11(32):4177-85. Review.

PMID:
16375739
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk